Argenx S.E

Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
  • TickerARGX
  • ISINNL0010832176
  • ExchangeEuronext Brussels
  • SectorPharmaceuticals & Biotechnology
  • CountryNetherlands

ARGENX sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of ARGENX (BE), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date August 4, 2020, the closing price was EUR 195.50 and its target price was estimated at EUR 152.20.

Wedbush Research

Wedbush Morning Call - Aug 03 2020 6:53AM

Valérie GASTALDY

Short term view - ARGENX SE : The trend is bullish.

The trend is bullish. Prices are making further progress. The targets are at €82.40 and then €94.80. The break of €58.50 would endanger the trend.

Valérie GASTALDY

Analyse court terme - ARGENX SE : La tendance est haussière.

La tendance est haussière. La progression des cours se poursuit. Les objectifs sont à 82,40 € puis 94,80 €. La rupture de 58,50 € mettrait la tendance en danger.

Valérie GASTALDY

Short term view - ARGENX SE : The background trend is clearly bearish.

The background trend is clearly bearish. Prices are falling again, but the movement has become hesitant. The next support is at €58.50. The background trend would be questioned should prices rise above €94.80.

Valérie GASTALDY

Analyse court terme - ARGENX SE : La tendance de fond est clairement orientée à la baisse.

La tendance de fond est clairement orientée à la baisse. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 58,50 €. La tendance de fond serait remise en cause en cas de franchissement de 94,80 €.

Jérôme VINERIER

Analyse moyen terme - ARGENX SE : La tendance est haussière.

La tendance est haussière. La progression des cours se poursuit. Les objectifs sont à 94,80 € puis 119,80 €. La rupture de 18,80 € mettrait la tendance en danger.

Wedbush Research

Wedbush Morning Call - Aug 03 2020 6:53AM

David Nierengarten ...
  • Jeffrey La Rosa
  • Matthew Barcus

2Q20 Earnings; Some Cusatuzumab Setbacks, but Efgartigimod Story Intact

Wedbush Research

Wedbush Morning Call - Jul 26 2020 6:53PM

ARGENX sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of ARGENX (BE), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date August 4, 2020, the closing price was EUR 195.50 and its target price was estimated at EUR 152.20.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Expert Corporate Governance Service (ECGS)

Argenx - EGM 25 November 2019

In general, Argenx is in compliance with the Dutch regulations relating to the organisation and procedures of the Extraordinary General Meeting. Under ITEM 3, the board of directors seeks approval to amend the Company’s stock option plan ("the Plan"). Although ECGS has no (major) concerns over the proposed amendments, it notes that Plan allows for a (potential) aggregate capital increase of 14.5% of the Company’s issued share capital, which exceeds ECGS’guidelines. In addition, ECGS considers the vesting period for time vesting awards (of between 1 and 3 years) too short. Based on the above, ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch